A large prospective biomarker study showed that serum NfL levels increased across hospitalized COVID-19 patients despite neurological manifestations, whereas CSF NfL levels increased specifically in patients with CNS inflammation, including encephalitis and acute disseminated encephalomyelitis, but not in patients with encephalopathy or GBS [83]. The gene discussed is NEFL; the disease is Guillain-Barre syndrome.